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Ventricular Arrhythmias
After Cardiac Surgery
Failing the Stress Test*
David S. Frankel, MD
Philadelphia, Pennsylvania
Implantable cardioverter defibrillators (ICDs) are well-
established, life-saving devices when implanted after resus-
citated ventricular fibrillation (VF) or ventricular tachycar-
dia (VT) arrests (1–3). Accordingly, the American College
of Cardiology/American Heart Association/Heart Rhythm
Society guidelines recommend ICDs for secondary preven-
tion after VF or VT arrest once completely reversible causes
have been excluded (4). Unfortunately, identifying com-
pletely reversible causes is easier said than done. For
example, in the AVID (Antiarrhythmics Versus Implant-
able Defibrillators) trial, patients considered to have revers-
ible causes of ventricular arrhythmias were excluded from
enrollment (1). In a registry substudy, these patients had
mortality rates similar to those considered to have irrevers-
ible causes of arrest who were randomized to antiarrhyth-
mic treatment (5). Thus, we must acknowledge our
limitations in classifying the cause of an arrest as revers-
ible or irreversible.
See page 2664
With inotrope use, volume and electrolyte shifts, and
periods of ischemia and reperfusion, the days after cardiac
surgery can be thought of as a “stress test,” full of potentially
reversible causes of VF and VT. Despite these triggers, the
reported incidence of post-operative ventricular arrhythmias
(POVAs) is only 1% to 3% (6,7). Nevertheless, the number
of patients undergoing cardiac surgery is large, and therefore
POVAs are frequently encountered. Unfortunately, the
natural history of POVA has not been well described. Do
patients experiencing POVA remain at high risk for sudden
cardiac death after the perioperative period or does their risk
normalize as the “stressing” factors are reversed? Clearly,
there are reasons to remain concerned. Patients with mono-
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capable of supporting macrore-entry, specifically myocardial
scar caused by infarction or other disease processes harbor-
ing protected isthmuses of surviving, slowly conducting
myocytes. This same substrate could again manifest re-entry
at a later time. Along similar lines, those experiencing VF
shortly after cardiac surgery may have more profound heart
failure, ischemia, hypertrophy, or other predisposing elec-
trical abnormalities, which would continue to put them at
risk for VF in the future.
In this issue of the Journal, El-Chami et al. (8) shed light
on this important topic. They report the incidence, predic-
tors, and natural history of POVA among 14,720 patients
undergoing cardiac surgery at Emory University between
2004 and 2010. POVA was defined as VT or VF lasting
30 s or requiring treatment with antiarrhythmic medica-
tion, cardioversion, or defibrillation. Baseline and surgical
characteristics were retrospectively collected from the Soci-
ety of Thoracic Surgeons (STS) National Database, as was
the incidence of POVA. Consistent with prior reports,
POVA was relatively uncommon, occurring in only 1.7% of
patients. In multivariate analysis, older age, lower left
ventricular ejection fraction (LVEF), emergent surgery, and
peripheral vascular disease were associated with an increased
risk of POVA, whereas off-pump surgery was associated
with a lower incidence of POVA. Before discharge, 8% of
patients underwent ICD implantation, and antiarrhythmic
medications were initiated in 34% of patients. The authors
then assessed mortality using the Social Security Death
Index. POVA was associated with increased mortality, both
before hospital discharge and in the following year.
Several limitations of this study are worth noting, pri-
marily related to the retrospective study design and sources
of data. First, important baseline characteristics, including
conduction abnormalities, history of atrial arrhythmias, and
presence of an ICD before surgery, were not collected in the
STS database and therefore were not available for analysis.
Second, the incidence of POVA may have been underesti-
mated if reporting to the STS database was incomplete.
Third, the nature of POVA (VF vs. VT) was determined in
only 55% of patients, and the timing relative to surgery in
only 62% of patients. Data regarding concurrent use of
inotropes and hemodynamic significance of postoperative
VT are missing entirely. Finally, no information is
available regarding the incidence of ventricular arrhyth-
mias, appropriate ICD therapies, or cause of death during
follow-up.
Despite these limitations, the study by El-Chami et al.
(8) is the largest series to date examining POVA and clearly
demonstrates a markedly increased mortality in the days and
years that follow cardiac surgery. In fact, after excluding
in-hospital deaths, the 1-year mortality among those with
POVA was 18.5%, nearly identical to those randomized to
antiarrhythmic medications in the AVID trial (1). Thus, the
present study suggests that the stresses after cardiac surgery
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Does this mean that all patients with POVA should have
an ICD implanted regardless of the timing and circum-
stances of the arrhythmia? The authors attempt to answer
this question by comparing those with POVA who died in
follow-up to those with POVA who lived through the study
period. Those with POVA who died in follow-up were
older and more likely to have VF as opposed to VT. In
addition, there were nonsignificant trends toward lower
LVEF and greater incidence of myocardial infarction before
surgery among those with POVA who did not survive.
Patients with POVA occurring within 48 h of surgery had
lower early mortality but equivalent long-term survival
compared with patients with POVA occurring after 48 h.
Of note, these factors increased the risk of all-cause death,
but ICDs only treat ventricular arrhythmias, and unfortu-
nately, no data are provided regarding ventricular arrhyth-
mias in follow-up. Therefore, it is impossible to determine
what proportion of these deaths would have been prevented
by ICD implantation.
In conclusion, what can we learn from this important
study by El-Chami et al. (8)? Ventricular arrhythmias after
cardiac surgery convey a poor prognosis, similar to that in
other secondary prevention cohorts. Older patients with
prior myocardial infarctions, lower LVEF, and VF rather
than VT have higher long-term mortality. Those who
experience POVA after the initial 48 h postoperative period
also seem to be at greater risk. The next step in improving
our understanding of POVA is a case-control study com-
paring those with POVA who continue to have ventricular
arrhythmias requiring ICD therapies or causing death with
those in whom POVA was a completely reversible event.
Until such information is available to guide our decision
making, how should we treat patients who fail their peri-
operative “stress test?” ICDs should be implanted in the
majority of those having VF or hemodynamically unstable
VT after the initial 48 h postoperative period and not taking
inotropes at the time of arrest. The more challenging tpopulation includes those with POVA earlier than 48 h or
while still taking inotropes. At the very least, close
follow-up is needed. Additional options include electro-
physiology study to further define risk or a wearable defi-
brillator for a period of time after discharge, when the risk
of death is particularly high.
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